Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo

Journal of the American Academy of Dermatology

Volumn 76, Issue 5, 2017, Pages 863-870

  Larsabal, Maiana ^a   Marti, Aurélie ^a   Jacquemin, Clément ^b   Rambert, Jérôme ^b   Thiolat, Denis ^b   Dousset, Léa ^a   Taieb, Alain ^a,b   Dutriaux, Caroline ^a   Prey, Sorilla ^a   Boniface, Katia ^a,b   Seneschal, Julien ^a,b  

^a HÔPITAL SAINT ANDRÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

anti programmed cell death 1 therapy; nivolumab; pembrolizumab; vitiligo; vitiligo like lesions

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; NIVOLUMAB; PEMBROLIZUMAB; TUMOR NECROSIS FACTOR; ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR3; CXCL10 PROTEIN, HUMAN; CXCR3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; AUTOIMMUNE THYROIDITIS; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FAMILY HISTORY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; MALE; MEDICAL HISTORY; METASTASIS; METASTATIC MELANOMA; PHOTOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; VITILIGO; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; DRUG ERUPTIONS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CXCL10; DRUG ERUPTIONS; FEMALE; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; PHOTOGRAPHY; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSPECTIVE STUDIES; RECEPTORS, CXCR3; TUMOR NECROSIS FACTOR-ALPHA; VITILIGO; YOUNG ADULT;

EID: 85009508824     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.10.044     Document Type: Article

References (20)

1. 1 Hamid, O., Robert, C., Daud, A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369 (2013), 134–144.
2. 2 Robert, C., Long, G.V., Brady, B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
3. 3 Robert, C., Ribas, A., Wolchok, J.D., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial. Lancet 384 (2014), 1109–1117.
4. 4 Michot, J.M., Bigenwald, C., Champiat, S., et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54 (2016), 139–148.
5. 5 Hua, C., Boussemart, L., Mateus, C., et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152 (2016), 45–51.
6. 6 Taieb, A., Picardo, M., Clinical practice. Vitiligo. N Engl J Med 360 (2009), 160–169.
7. 7 Watanabe, R., Gehad, A., Yang, C., et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med, 7, 2015, 279ra39.
8. 8 Bertolotti, A., Boniface, K., Vergier, B., et al. Type I interferon signature in the initiation of the immune response in vitiligo. Pigment Cell Melanoma Res 27 (2014), 398–407.
9. 9 Rashighi, M., Agarwal, P., Richmond, J.M., et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med, 6, 2014, 223ra23.
10. 10 Ezzedine, K., Eleftheriadou, V., Whitton, M., van Geel N., Vitiligo, Lancet 386 (2015), 74–84.
11. 11 Boniface, K., Taieb, A., Seneschal, J., New insights into immune mechanisms of vitiligo. G Ital Dermatol Venereol 151 (2016), 44–54.
12. 12 Taieb, A., Picardo, M., VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 20 (2007), 27–35.
13. 13 Diallo, A., Boniface, K., Jouary, T., et al. Development and validation of the K-VSCOR for scoring Koebner's phenomenon in vitiligo/non-segmental vitiligo. Pigment Cell Melanoma Res 26 (2013), 402–407.
14. 14 Gey, A., Diallo, A., Seneschal, J., et al. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms. Br J Dermatol 168 (2013), 756–761.
15. 15 Naveh, H.P., Rao, U.N., Butterfield, L.H., Melanoma-associated leukoderma - immunology in black and white?. Pigment Cell Melanoma Res 26 (2013), 796–804.
16. 16 Rosenberg, S.A., White, D.E., Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 19 (1996), 81–84.
17. 17 Peng, W., Liu, C., Xu, C., et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 72 (2012), 5209–5218.
18. + memory T cell responses to mouse melanoma. J Clin Invest 121 (2011), 1797–1809.
19. 19 Gauthier, Y., Cario Andre, M., Taieb, A., A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?. Pigment Cell Res 16 (2003), 322–332.
20. 20 Picardo, M., Dell'Anna, M.L., Ezzedine, K., et al. Vitiligo. Nat Rev Dis Primers, 1, 2015, 15011.